Endogenous fungal endophthalmitis: risk factors, clinical features, and treatment outcomes in mold and yeast infections
© Sridhar et al.; licensee Springer. 2013
Received: 16 July 2013
Accepted: 2 September 2013
Published: 20 September 2013
The purpose of the current study was to analyze risk factors, clinical features, and treatment outcomes in patients with endogenous fungal endophthalmitis with yeast and mold infections. For this retrospective consecutive case series, microbiologic and clinical records were reviewed to identify all patients with intraocular culture-proven endogenous fungal endophthalmitis treated at a single institution between January 1, 1990 and December 31, 2011.
Sixty-seven eyes of 53 patients were identified; 51 eyes of 39 patients had positive cultures for yeast and 16 eyes of 14 patients had positive cultures for molds. Patients with molds as a causative organism had significantly shorter duration of symptoms prior to diagnosis (molds 3.8 days, yeast 21.0 days, p = 0.002), were more likely to be receiving iatrogenic immunosuppression (molds 57.1%, yeast 7.7%, p = 0.001), have a history of whole-organ transplantation (molds 35.7%, yeast 2.6%, p = 0.001), and were more likely to have hypopyon at the time of diagnosis (molds 37.5%, yeast 6.0%, p = 0.001). Patients with endogenous endophthalmitis caused by molds had significantly worse visual acuity at the time of diagnosis (logMAR visual acuity molds 1.80, yeast 1.15, p = 0.008) and at final visit (logMAR visual acuity molds 1.97, yeast 1.05, p = 0.005) compared to those patients with yeast as a causative organism. There was no significant difference in the rate of retinal detachment between the two groups (mold 12.5%, yeast 30.6%, p = 0.201). Patients with cultures positive for mold were significantly more likely to undergo enucleation (molds 25.0%, yeast 0%, p < 0.001).
Systemic risk factors for patients with endogenous fungal endophthalmitis caused by molds were iatrogenic immunosuppression and a history of whole-organ transplantation. Shorter duration of symptoms before diagnosis and higher rates of hypopyon occurred in mold cases. While endogenous fungal endophthalmitis is generally associated with poor visual acuity outcomes, infection with mold species was associated with worse visual acuity on presentation and on final follow-up than infection with yeast species. Enucleation rates were much higher in mold cases.
Endogenous fungal endophthalmitis is a serious ocular condition associated with poor visual outcomes [1–3]. Most patients with this entity have predisposing systemic risk factors, although it may occur rarely in healthy immunocompetent individuals [4, 5]. In previous reports, the most common organism causing endogenous fungal endophthalmitis was the yeast species Candida albicans, followed by molds such as Aspergillus species [6–8].
The purpose of the current study was to analyze and report differences in risk factors, clinical presentation, and treatment outcomes between patients with endogenous fungal endophthalmitis caused by yeast and patients with endogenous fungal endophthalmitis caused by molds.
The Institutional Review Board approval was obtained from the University of Miami Miller, School of Medicine Sciences Subcommittee for the Protection of Human Subjects. A search of the ocular microbiology department database was performed to identify all patients with positive vitreous tap and vitrectomy specimen cultures for fungal species between January 1, 1990 and December 31, 2011. Medical records were subsequently reviewed to include those patients with a clinical course consistent with endogenous fungal endophthalmitis. The included patients’ medical records were reviewed for presenting clinical features, relevant patient past medical history, and treatment outcomes. Some of the patients included in this study were previously reported without statistical comparison in a series published by Lingappan et al. . Fungal cultures and identification were performed as previously described in that series [9, 10].
Fungal culture results were considered positive when there was growth of the same organism on two or more solid media at the inoculation site, or when the organism grew on one culture media and was noted on a stained smear (gram, Giemsa, or Gomori methenamine silver) . Treatment and management decisions were made by the individual treating physicians without a predefined study protocol.
For statistical analysis, the Snellen visual acuity (VA) was converted to logarithm of minimal angle of resolution (logMAR) equivalents and VA of count fingers, hand motion, light perception, and no light perception were assigned logMAR values of 1.85, 2.3, 2.7, and 3.0, respectively, as previously described [12, 13]. The logMAR VA is presented as mean ± standard deviation. Presenting and final VA was compared between the yeast and mold group using a Student’s t test. The difference in presenting VA and last recorded VA was also compared between the two groups using a Student’s t test. A Pearson chi-square test was used to compare presenting symptoms/signs, risk factors, initial treatments, enucleations, and complication between the two groups. A p value of < 0.05 was considered statistically significant.
Microbiology of endogenous fungal endophthalmitis
Systemic risk factors for endogenous fungal endophthalmitis
History of transplant
Positive systemic culturea
Clinical features of endogenous fungal endophthalmitis
Duration of symptoms (mean days ± SD)
21.0 ± 32.9
3.8 ± 5.4
Diffuse anterior and posterior inflammation
Anterior inflammation only
Posterior inflammation only
Initial management strategies for endogenous fungal endophthalmitis
Local ocular therapy
Treatment outcomes of endogenous fungal endophthalmitis
Visual Acuity (VA)
n = 39 (51 eyes)
n = 14 (16 eyes)
1.15 (± 0.78)
1.80 (± 0.80)
logMAR VA (+/− SD)
Final mean logMAR
1.05 (± 1.01)
1.97 (± 1.18)
VA (± SD)
0.11 (± 0.98)
−0.17 (± 1.24)
logMAR VA (± SD)
Multiple IVF injections
The clinical diagnosis of endogenous fungal endophthalmitis has been well described in previous case series and case reports [1, 6, 14, 15]. While there have been descriptions of the differences between patients with yeast infection and patients with mold infection, no large head-to-head statistical comparisons of culture-proven cases have been previously reported .
In the current study, endogenous endophthalmitis caused by molds, consisting mainly of Aspergillus species, was frequently associated with history of iatrogenic immunosuppression and organ transplantation. In models of invasive aspergillosis impaired neutrophil function has been shown to play a major role in the development of infection, and prolonged steroid use or other immunosuppression may depress neutrophil function . Riddell et al. previously reported in a review of the literature that 43% of patients with endogenous Aspergillus endophthalmitis had received prior treatment with corticosteroids . The current study also demonstrated a significantly shorter duration of symptoms for patients presenting with endogenous endophthalmitis caused by molds. Infected eyes were also more likely to have a hypopyon. Aspergillus has been shown in histopathologic specimens to prominently invade through blood vessel walls in the choroid leading to necrosis and more rapid involvement of the vitreous . As such, infection with more virulent mold organisms has been shown in the literature to correlate with worse visual acuity outcomes and higher rates of enucleation, as it did in the current study [1, 6]. Given the fulminant course of mold infections, patients often require systemic antifungal therapy, as demonstrated in the current study.
In contrast, patients with endogenous endophthalmitis caused by yeast presented more indolently and with better visual acuities, matching descriptions in the literature . Shen et al. previously reported 29 eyes with endogenous fungal endophthalmitis, and none of the mold cases achieving final visual acuity of 20/200 or better; in contrast, 53% of Candida cases achieved that outcome . Due to less clear patient histories and nonspecific examination findings mimicking uveitis, misdiagnosis of Candida endophthalmitis has been reported to approach 50% . Thus, it is imperative to investigate for risk factors such as recent hospitalization, recent surgery, and intravenous drug use and entertain a diagnosis of fungal endophthalmitis when approaching the uveitis patient with progressive signs and symptoms.
Retinal detachment was a frequent event in the follow-up course for patients in both groups. Retinal detachment is associated with poor visual outcome and is a potential complication of vitrectomy for endophthalmitis [20, 21]. One proposed mechanism is post-operative peripheral vitreous contraction inducing retinal breaks . However, in the Endophthalmitis Vitrectomy Study, there was no significant difference in the rate of retinal detachment between patients undergoing needle tap and vitrectomy biopsy . It was recently postulated that early vitrectomy in endogenous endophthalmitis caused by yeast might reduce the incidence of retinal detachment . Sallam et al. reviewed 44 eyes with Candida endophthalmitis and reported that eyes that underwent vitrectomy within a week of presentation resulted in a retinal detachment rate of 8% versus 41% in those eyes with delayed vitrectomy.
Pars plana vitrectomy was frequently utilized as the initial management strategy for patients in both groups of the current study. It has been suggested that early vitrectomy is preferable for these patients since vitreous paracentesis may not obtain an adequate vitreous sample of the localized infection. Endogenous fungal endophthalmitis classically begins with choroidal seeding and eventually invades the vitreous cavity . In the current series, the most common isolate was C. albicans followed by Aspergillus fumigatus. This is in accordance with previously reported results [24, 25]. Of note, polymerase chain reaction (PCR) testing has shown to be more rapid and sensitive than traditional mycology cultures in diagnosing fungal endophthalmitis and is now employed at many medical centers .
In patients with a suspected infection, a diagnostic vitrectomy may be considered initially. Intravitreal therapy can be specifically targeted once appropriate stains and culture results are obtained. Oral antifungal therapy is also considered, usually fluconazole or voriconazole. Depending on the clinical response to initial treatment, intravitreal injections can be given until the infectious process resolves. Patients can be monitored closely for retinal detachment. Although there are early reports proposing the use of intravitreal corticosteroids as an adjunct, there is no well-designed prospective, comparative trial addressing this point and as such, intravitreal steroids are not recommended given the risk of inhibiting the host immune response [27, 28].
The current study is limited by its retrospective design as well its relatively small number of patients. Rapid and sensitive PCR testing was not available for clinical use at our institution during the entire study period. Patients had quite variable follow-up and data could be missing from the chart review. Patients were identified based on positive intraocular cultures and thus cases of presumed endogenous endophthalmitis in which cultures were not obtained may have been excluded. In spite of these limitations, this study demonstrates and reinforces key differences between endogenous endophthalmitis caused by molds compared to yeasts.
Patients with endogenous endophthalmitis caused by molds were more likely to be receiving iatrogenic immunosuppression and have a history of whole-organ transplantation than those patients with endogenous endophthalmitis caused by yeast. Shorter duration of symptoms before diagnosis and higher rates of hypopyon occurred in mold cases. While endogenous fungal endophthalmitis is generally associated with poor visual acuity outcomes, infection with mold species was associated with worse visual acuity on presentation and on final follow-up than infection with yeast species. Enucleation rates were much higher in mold cases.
This research was funded in part by an unrestricted grant from Research to Prevent Blindness Inc., New York, NY, USA and the National Institutes of Health NEI Center Grant P30 EY014801.
- Schiedler V, Scott IU, Flynn HW Jr, Davis JL, Benz MS, Miller D: Culture-proven endogenous endophthalmitis: clinical features and visual acuity outcomes. Am J Ophthalmol 2004,137(4):725–731.PubMedGoogle Scholar
- Chhablani J: Fungal endophthalmitis. Expert Rev Anti Infect Ther 2011,9(12):1191–1201. 10.1586/eri.11.139PubMedView ArticleGoogle Scholar
- Lingappan A, Wykoff CC, Albini TA, Miller D, Pathengay A, Davis JL, Flynn HW Jr: Endogenous fungal endophthalmitis: causative organisms, management strategies, and visual acuity outcomes. Am J Ophthalmol 2012,153(1):162–166.e1. 10.1016/j.ajo.2011.06.020PubMedView ArticleGoogle Scholar
- Kostick DA, Foster RE, Lowder CY, Meyers SM, McHenry MC: Endogenous endophthalmitis caused by Candida albicans in a healthy woman. Am J Ophthalmol 1992,113(5):593–595.PubMedView ArticleGoogle Scholar
- Mamandhar A, Bajracharya L: Endogenous aspergillus endophthalmitis in a healthy individual. Nepal J Ophthalmol 2012,4(7):179–183.PubMedGoogle Scholar
- Essman TF, Flynn HW Jr, Smiddy WE, Brod RD, Murray TG, Davis JL, Rubsamen PE: Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis. Ophthalmic Surg Lasers 1997,28(3):185–194.PubMedGoogle Scholar
- Riddell Iv J, McNeil SA, Johnson TM, Bradley SF, Kazanjian PH, Kauffman CA: Endogenous Aspergillus endophthalmitis: report of 3 cases and review of the literature. Medicine (Baltimore) 2002,81(4):311–320. 10.1097/00005792-200207000-00007View ArticleGoogle Scholar
- Binder MI, Chua J, Kaiser PK, Procop GW, Isada CM: Endogenous endophthalmitis: an 18-year review of culture-positive cases at a tertiary care center. Medicine (Baltimore) 2003,82(2):97–105. 10.1097/00005792-200303000-00004View ArticleGoogle Scholar
- Sutton DA, Fothergill AW, Rinaldi MG: Guide to clinically significant fungi. 1st edition. Baltimore: Williams & Wilkins; 1997:471.Google Scholar
- Larone DH: Medically important fungi: a guide to identification. 4th edition. Washington, D.C: ASM Press; 2002:409.Google Scholar
- Rebell GC, Forster RK In: Manual of clinical microbiology. In Fungi of keratomycosis. 3rd edition. Washington, D.C: American Society for Microbiology; 1980:553–561.Google Scholar
- Schulze-Bonsel K, Feltgen N, Burau H, Hansen L, Bach M: Visual acuities “hand motion” and “counting fingers” can be quantified with the Freiburg visual acuity test. Invest Ophthalmol Vis Sci 2006, 47: 1236–1240. 10.1167/iovs.05-0981PubMedView ArticleGoogle Scholar
- Bach M, Schulze-Bonsel K, Feltgen N, Burau H, Hansen L: Author response: numerical imputation for low vision states [electronic letter]. Invest Ophthalmol Vis Sci 2007.Google Scholar
- Shrader SK, Band JD, Lauter CB, Murphy P: The clinical spectrum of endophthalmitis: incidence, predisposing factors, and features influencing outcome. J Infect Dis 1990,162(1):115–120. 10.1093/infdis/162.1.115PubMedView ArticleGoogle Scholar
- Connell PP, O’Neill EC, Amirul Islam FM, Buttery R, McCombe M, Essex RH, Roufail E, Lash S, Wolffe B, Clark B, Chiu D, Campbell W, Allen P: Endogenous endophthalmitis associated with intravenous drug abuse: seven-year experience at a tertiary referral center. Retina 2010,30(10):1721–1725. 10.1097/IAE.0b013e3181dd6db6PubMedView ArticleGoogle Scholar
- Rao NA, Hidayat AA: Endogenous mycotic endophthalmitis: variations in clinical and histopathologic changes in candidiasis compared with aspergillosis. Am J Ophthalmol 2001,132(2):244–251. 10.1016/S0002-9394(01)00968-0PubMedView ArticleGoogle Scholar
- Anand AR, Therese KL, Madhavan HN: Spectrum of aetiological agents of postoperative endophthalmitis and antibiotic susceptibility of bacterial isolates. Indian J Ophthalmol 2000, 48: 123.PubMedGoogle Scholar
- Oude Lashof AM, Rothova A, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Schlamm HT, Oborska IT, Rex JH, Kullberg BJ: Ocular manifestations of candidemia. Clin Infect Dis 2011,53(3):262–268. 10.1093/cid/cir355PubMedView ArticleGoogle Scholar
- Shen X, Xu G: Vitrectomy for endogenous fungal endophthalmitis. Ocul Immunol Inflamm 2009,17(3):148–152. 10.1080/09273940802689396PubMedView ArticleGoogle Scholar
- Foster RE, Rubsamen PE, Joondeph BC, Flynn HW Jr, Smiddy WS: Concurrent endophthalmitis and retinal detachment. Ophthalmology 1994,101(3):490–498.PubMedView ArticleGoogle Scholar
- Doft BM, Kelsey SF, Wisniewski SR: Retinal detachment in the endophthalmitis vitrectomy study. Arch Ophthalmol 2000,118(12):1661–1665. 10.1001/archopht.118.12.1661PubMedView ArticleGoogle Scholar
- Flynn HW Jr, Scott IU: Legacy of the endophthalmitis vitrectomy study. Arch Ophthalmol 2008,126(4):559–561. 10.1001/archopht.126.4.559PubMedView ArticleGoogle Scholar
- Sallam A, Taylor SR, Khan A, McCluskey P, Lynn WA, Manku K, Pacheco PA, Lightman S: Factors determining visual outcome in endogenous candida endophthalmitis. Retina 2012,32(6):1129–1134. 10.1097/IAE.0b013e31822d3a34PubMedView ArticleGoogle Scholar
- Zhang YQ, Wang WJ: Treatment outcomes after pars plana vitrectomy for endogenous endophthalmitis. Retina 2005,25(6):746–750. 10.1097/00006982-200509000-00010PubMedView ArticleGoogle Scholar
- Lamaris GA, Esmaeli B, Chamilos G, et al.: Fungal endophthalmitis in a tertiary care cancer center: a review of 23 cases. Eur J Clin Microbiol Infect Dis 2008,27(5):343–347. 10.1007/s10096-007-0443-9PubMedView ArticleGoogle Scholar
- Anand A, Madhavan H, Neelam V, Lily T: Use of polymerase chain reaction in the diagnosis of fungal endophthalmitis. Ophthalmology 2001,108(2):326–330. 10.1016/S0161-6420(00)00517-0PubMedView ArticleGoogle Scholar
- Coats ML, Peyman GA: Intravitreal corticosteroids in the treatment of exogenous fungal endophthalmitis. Retina 1992,12(1):46–51. 10.1097/00006982-199212010-00010PubMedView ArticleGoogle Scholar
- Majji AB, Jalali S, Das T, Gopinathan U: Role of intravitreal dexamethasone in exogenous fungal endophthalmitis. Eye (Lond) 1999,13(Pt 5):660–665.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.